A Phase 2 Study of MEK 1/2 Inhibitor Trametinib in Combination With AKT Inhibitor GSK2141795 in Acute Myeloid Leukemia (AML) With RAS Mutations
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 08 Jun 2016
At a glance
- Drugs Trametinib (Primary) ; Uprosertib (Primary)
- Indications Acute myeloid leukaemia; Acute myelomonocytic leukaemia
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 02 Jun 2016 Status changed from recruiting to active, no longer recruiting.
- 15 Apr 2016 Status changed from suspended to recruiting.